TaiMed Biologics Inc.
Taipei Exchange 4147.TWO
TaiMed Biologics Inc. Debt to Equity Ratio for the year ending December 31, 2023: 0.29
-
TaiMed Biologics Inc. Debt to Equity Ratio for the year ending December 31, 2022 was 0.28, a 46.32% change year over year.
-
TaiMed Biologics Inc. Debt to Equity Ratio for the year ending December 31, 2021 was 0.19, a 15.73% change year over year.
-
TaiMed Biologics Inc. Debt to Equity Ratio for the year ending December 31, 2020 was 0.17, a 1,658.05% change year over year.
-
TaiMed Biologics Inc. Debt to Equity Ratio for the year ending December 31, 2019 was 0.01, a 0.00% change year over year.
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Mr. Chin-Ming Chang Ph.D. |
| IPO Date | June 20, 2012 |
| Location | Taiwan |
| Headquarters | No. 607, Ruiguang Road |
| Employees | 79 |
| Sector | Healthcare |
| Industries | |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Past 5 years
USD 1.81
USD 3.03
StockViz Staff
February 5, 2025
Any question? Send us an email